Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-Dm1 in Vivo

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0743
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Structure-Based Design of Potent BCL-2/BCL-xL Inhibitors With Strong in Vivo Antitumor Activity

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2012English

Combined Inhibition of Notch Signaling and BCL-2/BCL-xL Results in Synergistic Antimyeloma Effect

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

Expression Profile of BCL-2, BCL-XL, and McL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

BCL-Xl Down-Regulation Suppresses the Tumorigenic Potential of NPM/ALK in Vitro and in Vivo

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

BCL-xL in Neuroprotection and Plasticity

Frontiers in Physiology
Physiology
2014English

The BCL-2 Proteins Noxa and BCL-xL Co-Ordinately Regulate Oxidative Stress-Induced Apoptosis

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2012English

Crystal Structure of ABT-737 Complexed With BCL-xL: Implications for Selectivity of Antagonists of the BCL-2 Family

Cell Death and Differentiation
Cell BiologyMolecular Biology
2007English

Apoptosis Is Augmented in High-Grade Serous Ovarian Cancer by the Combined Inhibition of BCL-2/BCL-xL and PARP

International Journal of Oncology
Cancer ResearchOncology
2017English

Expression of Beclin-1, BCL-2, BCL-xL, Bad, and Bax in HCV Patients in Relation to Grade of Hepatic Fibrosis

Archives of Infectious Diseases & Therapy
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy